Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2019032472) HIGH AFFINITY ENGINEERED MATRIPTASE INHIBITOR
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2019/032472 International Application No.: PCT/US2018/045431
Publication Date: 14.02.2019 International Filing Date: 06.08.2018
IPC:
A61K 38/00 (2006.01) ,A61K 38/16 (2006.01) ,A61K 38/55 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38
Medicinal preparations containing peptides
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38
Medicinal preparations containing peptides
16
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38
Medicinal preparations containing peptides
16
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
55
Protease inhibitors
Applicants:
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY [US/US]; Office of the General Counsel Building 170, 3rd Floor, Main Quad P.O. Box 20386 Stanford, California 94305-2038, US
Inventors:
MITCHELL, Aaron; US
COCHRAN, Jennifer R.; US
Agent:
KEDDIE, James S.; US
Priority Data:
62/542,73308.08.2017US
62/549,37623.08.2017US
Title (EN) HIGH AFFINITY ENGINEERED MATRIPTASE INHIBITOR
(FR) INHIBITEUR DE MATRIPTASE MODIFIÉ PAR HAUTE AFFINITÉ
Abstract:
(EN) Provided herein, among other things, is a high affinity inhibitor of the matriptase protease. In some embodiments, the polypeptide comprises a first Kunitz domain that is at least 90% identical to the entire contiguous length of the KD2/1 fusion of SEQ ID NO:1. Methods for inhibiting a matriptase protease and methods for treating a matriptase-related disease or condition in a subject are also provided.
(FR) L'invention concerne, entre autres choses, un inhibiteur à haute affinité de la protéase de matriptase. Dans certains modes de réalisation, le polypeptide comprend un premier domaine de Kunitz qui est identique à au moins 90 % de toute la longueur contiguë de la fusion KD2/1 de la SEQ ID NO : 1. L'invention concerne également des procédés d'inhibition d'une protéase de matriptase et des procédés de traitement d'une maladie ou d'une affection liée à la matriptase chez un sujet.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)